Compare Salesforce Inc (CRM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs ResMed Inc. — how do they compare? Salesforce Inc trades at $228.49 (market cap $187.48B), while ResMed Inc. trades at $228.17 (market cap $31.89B). The key difference: Salesforce Inc is far larger — about 5.9× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and ResMed Inc. for 51 Days on average.
| CRM | RMD | |
|---|---|---|
Market Cap | $187.48B | $31.89B |
Volume | 6,155,822 | 618,314 |
Sector | Technology | Health |
52-Week High | $266.23 | $277.88 |
52-Week Low | $150.12 | $182.82 |
Typical Hold Time | 89 Days | 51 Days |
Enterprise Value | $217.82B | $31.24B |
Dividend Yield | 0.77% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected) and robust profitability (77.28% gross margin, 21.99% net margin). Technical indicators signal bearish momentum with resistance at $227 and support at $222. Recent news highlights AI-driven volatility but also underscores Salesforce's positioning as an Agentic AI beneficiary.
Outlook: Salesforce's discounted valuation (P/E 20.86 vs. historical averages) and AI monetization growth (Agentforce ARR up 200% YoY) present a buying opportunity, though near-term risks include sector-wide pressure and macroeconomic uncertainty. Analyst consensus remains strongly bullish with a $271.91 price target, suggesting ~21% upside.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
